ClinicalTrials.Veeva

Menu

Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy

Mount Sinai Hospital, Canada logo

Mount Sinai Hospital, Canada

Status

Active, not recruiting

Conditions

Hematologic Malignancy
Hypoxia
Post Hematopoietic Stem Cell Transplant
Immunocompromised
Pulmonary Infiltrates

Treatments

Device: High Flow Nasal Cannula or Low Flow Nasal Cannula

Study type

Interventional

Funder types

Other

Identifiers

NCT03168815
vSep2016

Details and patient eligibility

About

Pneumonia is a lung infection. Fiberoptic bronchoscopy is a test to diagnose the type of lung infection. While this procedure is being performed, a small amount of oxygen is delivered into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen of the patient may drop and an intervention such as increasing the oxygen flow, or placing the patient on a breathing machine is required. An alternative device called 'Optiflow' can provide high flow oxygen through nasal cannula, and is comfortable for patients. If Optiflow is used during bronchoscopy, it may prevent the blood oxygen from dropping.

Full description

Pneumonia is a lung infection that is a common complication in people with cancer, because of a weak immune system. Fiberoptic bronchoscopy is a test that is commonly used to help doctors diagnose the type of lung infection and treat it appropriately. It involves passing a thin tube with a camera at the end inside the lungs, and taking some fluid samples which are sent for analysis. While this procedure is being performed, a small amount of oxygen is delivered into the nose (low flow nasal cannula). Occasionally during this procedure, the blood oxygen of the patient may drop (even if the patient is receiving oxygen, and especially if the patient has severe pneumonia), and the procedure may have to be interrupted or prematurely stopped. If the oxygen level drops significantly, an intervention such as increasing the oxygen flow, or in the worst-case scenario temporarily placing the patient on a breathing machine is required. An alternative device called 'Optiflow' can provide high flow oxygen through nasal cannula, and is comfortable for patients. Optiflow was approved by Health Canada in 2006, and is commonly used in hospitals in Ontario and around the world to support patients whose blood oxygen is low. If Optiflow is used during bronchoscopy, it may prevent the blood oxygen from dropping.

Enrollment

98 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Adult patients ≥18 years scheduled to undergo FOB (as determined by their medical care team) who are immunocompromised (active hematologic malignancy or post hematopoietic stem cell transplant), and are hypoxic with pulmonary infiltrates. Hypoxia will be defined as requiring supplemental low flow oxygen ≥ 2L/min by nasal cannula to maintain SpO2 >90%.

Exclusion criteria

  1. requiring supplemental oxygen > 8L/min by nasal cannula;
  2. receiving HFNC before randomization;
  3. nasal deformity or packing precluding HFNC use;
  4. hypercapnia (PaCO2 > 60) or respiratory acidosis (pH <7.25);
  5. requiring NIV for over 1 hour or intubated.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

98 participants in 2 patient groups

High Flow Nasal Cannula (HFNC)
Experimental group
Description:
Oxygen is delivered at 50 L/min with FiO2 50% delivered for at least 5 min prior to FOB and throughout the procedure.
Treatment:
Device: High Flow Nasal Cannula or Low Flow Nasal Cannula
Low Flow Nasal Cannula (LFNC)
Active Comparator group
Description:
Oxygen is delivered at 6L/min applied for at least 5 minutes prior to FOB and throughout the procedure.
Treatment:
Device: High Flow Nasal Cannula or Low Flow Nasal Cannula

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems